Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 7/2022

22.03.2022 | Leukemia (A Aguayo, Section Editor)

Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections

verfasst von: Francisco Moreno-Sanchez, Brenda Gomez-Gomez

Erschienen in: Current Oncology Reports | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Patients with hematological malignancies are recognized for their high susceptibility and increased risk of developing infections associated with immunosuppression that can be caused by the infection itself or by the treatments that condition a decrease in the humoral and T lymphocyte response, so this review attempts to gather the main bacterial, viral, parasitic, and fungal agents that affect them and give recommendations for their approach and diagnosis.

Recent Findings

In recent years, with the discovery and use of new therapies including immunological and targeted treatments, it has been possible to improve the survival and response of patients with hematological malignancies; however, antimicrobial resistance has also increased; we have faced new and unknown microorganisms, such as the SARS-CoV-2 that caused the COVID-19 pandemic in the past year, and therefore, new risks and more severe infections are presented.

Summary

We present a review of the different circumstances where hematological malignancies increased the risk of infections and which microorganisms affect these patients, their characteristics, and the suggested prophylaxis.
Literatur
1.
Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53(8):798–806.PubMedCrossRef
2.
•• Nucci M, Anaissie EJ. Prevention of infections in patients with hematological malignancies. Neoplast Dis Blood. 2017;1047–62. https://​doi.​org/​10.​1007/​978-3-319-64263-5_​49. This article describe various strategies directed to the prevention of infections in patients with hematological malignancies, according to this risk-based strategy.
3.
Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13(10):2601–10.PubMedCrossRef
4.
CDC. COVID-19 vaccines for moderately or severely immunocompromised people. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases; 2022.
5.
Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639–45.PubMedCrossRef
6.
Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis. 2001;32(2):307–10.PubMedCrossRef
7.
• Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98(3):713–22 This study assess the risk factors associated with infections in the era of novel agents in myeloma patients.PubMedCrossRef
8.
Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–40.PubMedCrossRef
9.
Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135(5):715–9.PubMedCrossRef
10.
Engelich G, Wright DG, Hartshorn KL. Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis. 2001;33(12):2040–8.PubMedCrossRef
11.
Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45(2):228–33.PubMedCrossRef
12.
Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001;17(3):531–70 vii-viii.PubMedCrossRef
13.
Rolston KV. Review: Daptomycin for the treatment of gram-positive infections in neutropenic cancer patients. Clin Adv Hematol Oncol. 2008;6(11):815–7.PubMed
14.
Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160(4):501–9.PubMedCrossRef
15.
Holland T, Fowler VG Jr, Shelburne SA. 3rd. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis. 2014;59 Suppl 5(Suppl 5):S331–4.PubMedCrossRef
16.
Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30 Suppl 1:S51–9.PubMedCrossRef
17.
Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103(6):1103–13.PubMedCrossRef
18.
Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis. 2014;59 Suppl 5(Suppl 5):S335–9.PubMedCrossRef
19.
Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis. 2005;40 Suppl 4:S253–6.PubMedCrossRef
20.
Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation. Part I. Am Rev Respir Dis. 1991;143(6):1386–405.PubMedCrossRef
21.
Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741–51.PubMedCrossRef
22.
Ramsey PG, Rubin RH, Tolkoff-Rubin NE, Cosimi AB, Russell PS, Greene R. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine (Baltimore). 1980;59(3):206–22.CrossRef
23.
Ison MG, Hayden FG. Viral infections in immunocompromised patients: what’s new with respiratory viruses? Curr Opin Infect Dis. 2002;15(4):355–67.PubMedCrossRef
24.
• Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, et al. Management of CLL patients early in the COVID-19 pandemic: an international survey of CLL experts. Am J Hematol. 2020;95(8):E199–e203. This survey (April 2020) conducted the American Society of Hematology (ASH) to provide an online resource for frequently asked questions about care of patients with COVID-19 in the setting of hematologic malignancies including CLL.PubMedCrossRef
25.
Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106–11.PubMedCrossRef
26.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354–63.PubMedCrossRef
27.
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–43.PubMedCrossRef
28.
• The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19. Lancet Oncol. 2020;21(5):622–4. The UK Coronavirus Cancer Monitoring Project (UKCCMP) aims to collect, analyse, and disseminate in real time data from the UK cancer centres about SARS-CoV-2 infection rates in patients with cancer, and their outcomes in terms of COVID-19. This enables physicians to gain crucial insights to inform decision making.
29.
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18.PubMedPubMedCentralCrossRef
30.
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26(35):5684–8.PubMedPubMedCentralCrossRef
31.
Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20(12):2087–92.PubMedCrossRef
32.
Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol. 1979;72(4):617–21.PubMedCrossRef
33.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.PubMedCrossRef
34.
Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents. 2007;30(6):551–4.PubMedCrossRef
35.
Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48(6):772–86.PubMedCrossRef
36.
Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Investig. 1997;15(3):237–42.CrossRef
37.
Weber DM, Pellecchia JA. Varicella pneumonia: study of prevalence in adult men. JAMA. 1965;192:572–3.PubMedCrossRef
38.
Auguste P, Tsertsvadze A, Pink J, Court R, McCarthy N, Sutcliffe P, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):200.PubMedPubMedCentralCrossRef
39.
Auguste P, Madan J, Tsertsvadze A, Court R, McCarthy N, Sutcliffe P, et al. Identifying latent tuberculosis in high-risk populations: systematic review and meta-analysis of test accuracy. Int J Tuberc Lung Dis. 2019;23(11):1178–90.PubMedCrossRef
40.
Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549.PubMedPubMedCentralCrossRef
41.
Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med. 2019;40(4):721–39.PubMedCrossRef
42.
Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008;29(2):283–94.PubMedPubMedCentralCrossRef
43.
Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, Fuhrman C, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 2010;62(2):340–50.PubMedPubMedCentral
44.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253–62.PubMedCrossRef
45.
•• Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernández-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24 Suppl 2:S71–s82. This review from the group for infections in compromised hosts, analyze the safety of targeted and biological therapies from an Infectious Diseases perspective, and suggests preventive recommendations.PubMedCrossRef
Metadaten
Titel
Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections
verfasst von
Francisco Moreno-Sanchez
Brenda Gomez-Gomez
Publikationsdatum
22.03.2022
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 7/2022
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-022-01226-y

Weitere Artikel der Ausgabe 7/2022

Current Oncology Reports 7/2022 Zur Ausgabe

Cardio-oncology (JN Upshaw, Section Editor)

Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge

Neuroendocrine Neoplasms (NS Reed, Section Editor)

Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?

Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers

Breast Cancer (RA Leon Ferre, Section Editor)

Bystander effect of antibody–drug conjugates: fact or fiction?

Geriatric Oncology (L Balducci, Section Editor)

Treatment of Metastatic Melanoma in the Elderly

Palliative Medicine (A Jatoi, Section Editor)

The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise